NeoVax With Nivolumab Feasible in Platinum-Sensitive Ovarian Cancer Study

Clinical research laboratory preparing personalised vaccine doses
A phase 1 study finds NeoVax, a personalised neoantigen vaccine, feasible with nivolumab in platinum-sensitive ovarian cancer, with acceptable safety.
Read more

Disclaimer: Paid content authors may submit articles. Not all submissions are reviewed daily. The owner does not promote or endorse illegal activities like gambling, betting, casinos, or CBD.

Got it!
Close Welcome Bar